Diploma PLC (DPLM)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 6,890.00 |
|---|---|
| 52-week range | 4,970.00 – 7,980.00 |
| Return, 1 month / 3 months | −9.6% / −7.3% |
| Return, 1 year / 3 years | +25.4% / +149.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 28 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -13.1% |
| Average daily value traded | 5,026.74M GBX |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Diploma PLC is a group of specialised businesses that supply technical products and services to industrial and healthcare customers. Its operations include life sciences activities serving laboratories and medical customers, and controls and seals businesses supplying components and aftermarket support to industrial equipment makers and users. The company is based in the United Kingdom and operates across Europe and North America, with customers ranging from manufacturers and distributors to research and healthcare organisations.
On this site Diploma PLC appears as a stock on the London Exchange (UK), code DPLM, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Diploma PLC (DPLM) trades on the London Exchange in UK. It last closed at GBX 6,890.00 on 23 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 736 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.4% and over the last three months it fell 7.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.0% | ||
| From 52-week high | -13.1% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -7.3% | ||
| 6-month return | -1.5% | ||
| 12-month return, skipping the last month | 38.7% | ||
| Stability (higher is calmer) | 77 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.1% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 5,026.74M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 28 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −12.7% |
|---|---|
| 1 month | −9.6% |
| 3 months | −7.3% |
| 6 months | −1.5% |
| 1 year | +25.4% |
| 3 years | +149.9% |
| 5 years | +153.7% |
Signals
| 50-day / 200-day average | 7,440.70 / 6,690.84 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 186.46 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 May 2026 | GBP 0.1910 |
| 15 Jan 2026 | GBP 0.4410 |
| 29 May 2025 | GBP 0.1820 |
| 16 Jan 2025 | GBP 0.4200 |
| 23 May 2024 | GBP 0.1730 |
| 18 Jan 2024 | GBP 0.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.